luspatercept
Selected indexed studies
- Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. (N Engl J Med, 2020) [PMID:31914241]
- Luspatercept. (, 2006) [PMID:37094054]
- Luspatercept. (, 2012) [PMID:34648251]
_Worker-drafted node — pending editorial review._
Connections
luspatercept is a side effect of
Sources
- Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. (2020) pubmed
- Luspatercept. (2006) pubmed
- Luspatercept. (2012) pubmed
- Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial. (2024) pubmed
- Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. (2023) pubmed
- Luspatercept: a treatment for ineffective erythropoiesis in thalassemia. (2024) pubmed
- A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia. (2020) pubmed
- Luspatercept: First Approval. (2020) pubmed
- Luspatercept to treat β-thalassemia. (2020) pubmed
- How to use luspatercept and erythropoiesis-stimulating agents in low-risk myelodysplastic syndrome. (2025) pubmed